Classifying necrotising mpox as an AIDS-defining condition

Affiliations

¹ Skin, Neglected Tropical Diseases, and Sexually Transmitted Infections Section, Fight Infectious Diseases Foundation, University Hospital Germans Trias i Pujol, Badalona 08916, Spain. Electronic address: omitja@lluita.org.
² Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico.
³ Infectious Disease Department, Fight Infectious Diseases Foundation, University Hospital Germans Trias i Pujol, Badalona 08916, Spain.
⁴ Blizard Institute and SHARE Collaborative, Department of Infection and Immunity, Queen Mary University of London, London, UK.

Comment

Oriol Mitjà et al. Lancet. 2023.

. 2023 Nov 11;402(10414):1751-1752.

doi: 10.1016/S0140-6736(23)01896-2.

¹ Skin, Neglected Tropical Diseases, and Sexually Transmitted Infections Section, Fight Infectious Diseases Foundation, University Hospital Germans Trias i Pujol, Badalona 08916, Spain. Electronic address: omitja@lluita.org.
² Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico.
³ Infectious Disease Department, Fight Infectious Diseases Foundation, University Hospital Germans Trias i Pujol, Badalona 08916, Spain.
⁴ Blizard Institute and SHARE Collaborative, Department of Infection and Immunity, Queen Mary University of London, London, UK.

No abstract available

Comment in

Classifying necrotising mpox as an AIDS-defining condition - Authors' reply.
Núñez I, Valdés-Ferrer SI. Núñez I, et al. Lancet. 2023 Nov 11;402(10414):1752. doi: 10.1016/S0140-6736(23)01898-6. Lancet. 2023. PMID: 37951689 No abstract available.

Fulminant mpox as an AIDS-defining condition: useful or stigmatising?
Núñez I, Valdés-Ferrer SI. Núñez I, et al. Lancet. 2023 Mar 18;401(10380):881-884. doi: 10.1016/S0140-6736(23)00333-1. Epub 2023 Feb 21. Lancet. 2023. PMID: 36828002 No abstract available.